arrow_back Trending Legislation
Share share

Safe Medicine Act: Boosting US Drug Production and Safety

This bill aims to reduce US reliance on foreign generic drug suppliers, particularly from China. It directs government agencies to develop a strategy to increase domestic production of key medicines and ingredients and requires clear warnings on drugs from countries with manufacturing oversight issues. This is intended to improve the safety and availability of essential medicines for citizens.
Key points
Government must develop a plan to buy more US-made essential medicines and ingredients.
Agencies will work to increase domestic production of critical drugs over the next 5 years.
The FDA can require clear warnings on drug labels if they come from countries with known manufacturing issues.
Limits waivers that could allow buying foreign essential medicines over US-made ones for government use.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Safe Medicine Act
Print number: HR 5003
Sponsor: Rep. Posey, Bill [R-FL-8]
Process start date: 2021-08-10
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Safe Medicine Act: Boosting US Drug Production and Safety

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 5003.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-08-10.

What are the main provisions?

Key points include:

  • Government must develop a plan to buy more US-made essential medicines and ingredients.
  • Agencies will work to increase domestic production of critical drugs over the next 5 years.
  • The FDA can require clear warnings on drug labels if they come from countries with known manufacturing issues.
  • Limits waivers that could allow buying foreign essential medicines over US-made ones for government use.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Posey, Bill [R-FL-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Oversight and Investigations.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 5003

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Security